


Abacavir sulfate

Cat. No.:	HY-17423A
CAS No.:	188062-50-2
Molecular Formula:	C ₁₄ H ₁₈ N ₆ O _{1.5} H ₂ O ₄ S
Molecular Weight:	335.38
Target:	Reverse Transcriptase; Apoptosis; HIV; Telomerase
Pathway:	Anti-infection; Apoptosis; Cell Cycle/DNA Damage
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (149.08 mM; Need ultrasonic)
H₂O : 33.33 mg/mL (99.38 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.9817 mL	14.9085 mL	29.8169 mL
	5 mM	0.5963 mL	2.9817 mL	5.9634 mL
	10 mM	0.2982 mL	1.4908 mL	2.9817 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 10 mg/mL (29.82 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.45 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.45 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.45 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Abacavir sulfate (Abacavir Hemisulfate) is a competitive, orally active nucleoside reverse transcriptase inhibitor. Abacavir sulfate can inhibit the replication of HIV. Abacavir sulfate shows anticancer activity in prostate cancer cell lines. Abacavir sulfate can cross the blood-brain-barrier and suppresses telomerase activity^{[1][2][3]}.

In Vitro

Abacavir (15 and 150 μM, 0-120 h) sulfate inhibits cell growth, affects cell cycle progression, induces senescence and modulates LINE-1 mRNA expression in prostate cancer cell lines^[1].

Abacavir (15 and 150 μM , 18 h) sulfate significantly reduces cell migration and inhibits cell invasion^[1].
Abacavir sulfate induces fat apoptosis^[4].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	PC3, LNCaP and WI-38
Concentration:	15 and 150 μM
Incubation Time:	0, 24, 48, 72 and 96 h
Result:	Showed a dose-dependent growth inhibition on PC3 and LNCaP.

Cell Cycle Analysis^[1]

Cell Line:	PC3 and LNCaP
Concentration:	150 μM
Incubation Time:	0, 18, 24, 48, 72, 96 and 120 h
Result:	Caused a very high accumulation of cells in S phase in PC3 and LNCaP cells, and G2/M phase increment was observed in PC3 cells.

Cell Migration Assay^[1]

Cell Line:	PC3 and LNCaP
Concentration:	15 and 150 μM
Incubation Time:	18 h
Result:	Significantly reduced cell migration.

Cell Invasion Assay^[1]

Cell Line:	PC3 and LNCaP
Concentration:	15 and 150 μM
Incubation Time:	18 h
Result:	Significantly inhibited cell invasion.

In Vivo

Abacavir (0-7.5 $\mu\text{g}/\text{mL}$, 100 μL , intrascrotal administration; 100 and 200 mg/kg , p.o.; 4 h) sulfate dose-dependently promoted thrombus formation^[2].

Abacavir (50 $\text{mg}/\text{kg}/\text{d}$; i.p.; 14 days) sulfate with 0.1 $\text{mg}/\text{kg}/\text{d}$ Decitabine (HY-A0004) enhances survival of high-risk medulloblastoma-bearing mice^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male mice (9-weeks old, 22-30 g) - wild-type (WT) C57BL/6 or homozygous knockout (P2rx7 KO, B6.129P2-P2rx7 ^{tm1Gab/J}) ^[2]
Dosage:	2.5, 5 and 7.5 $\mu\text{g}/\text{mL}$, 100 μL or 100 and 200 mg/kg
Administration:	Intrascrotal or oral administration for 4 h

Result:	Dose-dependently promoted thrombus formation.
Animal Model:	NSG TM mice, patient-derived xenograft (PDX) cells of non-WNT/non-SHH, Group 3 and of SHH/ TP53-mutated medulloblastoma ^[3]
Dosage:	50 mg/kg/d with 0.1 mg/kg/d Decitabine
Administration:	Intraperitoneal injection, daily for 14 days
Result:	Inhibited tumor growth and enhanced mouse survival.

CUSTOMER VALIDATION

- Int J Antimicrob Agents. 2019 Dec;54(6):814-819.
- J Mol Liq. 2018 Feb;251:345-357.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Carlini F, et al. The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. PLoS One. 2010 Dec 3;5(12):e14221.
- [2]. Collado-Diaz V, et al. Abacavir Induces Arterial Thrombosis in a Murine Model. J Infect Dis. 2018 Jun 20;218(2):228-233.
- [3]. Gringmuth M, et al. Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir. Int J Mol Sci. 2022 Mar 30;23(7):3815.
- [4]. McComsey GA, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS. 2005 Jan 3;19(1):15-23.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA